Long-term effects of the treatment of acute lymphoblastic leukemia (ALL) in paediatric patients
With current treatments, the survival rate of children with ALL is now 85%. Despite this good prognosis, the long-term side effects of treatments can affect the future quality of life of patients.
Identify and analyze the side effects of treatment 3 years after remission of ALL, taking into account the perspective of patients with pediatric disease onset (or that of their caregivers) as a source of information.
A clinical and psychosocial study that will use the information provided directly by patients and their caregivers through the use of a validated ALAN scale (Acute Leukaemia Advocates Network) to report quality of life data. This pilot will be carried out in collaboration with the CLOSER project (GA 825749) and will also collect information from patients in Argentina, Chile and Uruguay.
Research is the heart of Share4Rare. By working together we can help to advance the research efforts in rare diseases. That's why we need you: join the community and participate in research!